The Latest Breaking News from NYSE

What 5 Analyst Ratings Have To Say About Spirit Realty Cap

Within the last quarter, Spirit Realty Cap (NYSE:SRC) has observed the following analyst ratings:

Benzinga · Feb 16, 2022

Expert Ratings For Medtronic

Within the last quarter, Medtronic (NYSE:MDT) has observed the following analyst ratings:

Benzinga · Feb 16, 2022

What 4 Analyst Ratings Have To Say About Devon Energy

Analysts have provided the following ratings for Devon Energy (NYSE:DVN) within the last quarter:

Benzinga · Feb 16, 2022

3 Roblox Analysts React To Q4 Earnings As Investors Pull Back

Gaming company Roblox Corp (NYSE: RBLX) reported bookings growth of 20% in the fourth quarter and reported record revenue and daily active user metrics for its full fiscal year.

Benzinga · Feb 16, 2022

Evercore ISI Downgrades This Used-Vehicle Retailer - Read Why

Evercore ISI analyst Michael Montani downgraded CarMax Inc (NYSE:KMX) to In-Line from Outperform with a price target of $120, down from $145, implying a 10% upside. Montani said CarMax took a profitable share throughout the calendar year 2021. He sees used vehicle pricing remaining "stubbornly high" with a new and used vehicle shortage likely to…

Benzinga · Feb 16, 2022

Loop Capital Bumps Up WESCO Price Target By 6%

Loop Capital analyst Chris Dankert raised the price target on WESCO International, Inc. (NYSE:WCC) to $170 (an upside of 32.4%) from $160 and maintained a Buy rating on the shares. The analyst cites the company's Q4 earnings beat and better than expected 2022 guidance. He also sees further upside potential to 2022-2023 estimates from increasing…

Benzinga · Feb 16, 2022

Merck Inks Oncology, Neurology Drug Discovery Pact With British Biotech, Curve Therapeutics

Privately-held Curve Therapeutics has inked a contract with Merck & Co Inc (NYSE: MRK) to discover and validate modulators of up to five therapeutic targets using its Microcycle technology, initially for oncology and neurology indications.

Benzinga · Feb 16, 2022

Read How Analysts Reacted To Allegion's Q4 Results

Analysts lowered the price target for Allegion PLC (NYSE:ALLE) post Q4 results. Mizuho analyst Brett Linzey lowered the price target to $145 (an upside of 26.7%) from $170 and maintained a Buy rating on the shares post the Q4 results. Linzey mentions Allegion's Q4 operational results were modestly ahead of expectations, with Americas driving the outperformance.…

Benzinga · Feb 16, 2022

SFL Registers 12% Sequential Revenue Growth In Q4

SFL Corp Ltd (NYSE: SFL) reported 

Benzinga · Feb 16, 2022

Vulcan Materials Clocks 37% Revenue Growth in Q4, Tops Steet View

Vulcan Materials Co (NYSE:VMC) reported a fourth-quarter revenue increase of 36.7% year-over-year to $1.61 billion, beating the consensus of $1.55 billion. Overall gross margin contracted by 386 bps to 21.9%. The operating earnings increased by 7.6% Y/Y to $211.3 million, and the margin contracted by 356 bps to 13.2%. Adjusted EBITDA was $383.4…

Benzinga · Feb 16, 2022